50 / 84
290
Ces Urol 2015; 19(4): 281–290
ORIGINÁLNÍ PRÁCE
16. Greco O, Powell TM, Marples B, Joiner MC, Scott SD.
Gene therapy vectors containing CArG elements
from the Egr1 gene are activated by neutron irradiation, cisplatin and doxorubicin. Cancer Gene Ther 2005
Jul; 12(7): 655–62.
17. Bruce ACH, Longo DL.
Longo eds. Clinical strategies for cancer treatment: The role of drugs. In: Bruce
A. Cancer Chemotherapy and Biotherapy. Principles and Practice. 5th ed. Philadelphia: Wolters Kluwer/
Lippincott Williams & Wilkins; 2011, 3–14.
18. Pritchard JR, Lauffenburger DA, Hemann MT.
Understanding resistance to combination chemothe‑
rapy. Drug Resist Updat 2012 Oct; 15(5–6): 249–257.
19. Moscow JA, Schneider E, Sikic BI, Morrow CS, Cowan KH.
Drug resistance and its clinical circumven‑
tion. In: Holland JF, Frei E, eds. Cancer Medicine. 8. ed. Shelton: PMPH-USA; 2010: 597–610.
20. Baguley BC.
Multidrug resistance in cancer. In: Baguley BC. Multi-Drug Resistance in Cancer. Methods
in Molecular, Biology vol. 596, New York: Humana Press/Springer; 2010, 1–14.
21. Persidis A.
Cancer multidrug resistance. Nature Biotechnol 1999 Jan; 17(1): 94–95.
22. O‘Connor R.
The pharmacology of cancer resistance. Anticancer Res 2007 May-Jun; 27(3A): 1267–1272.
23. Mohelníková-Duchoňová B, Souček P.
Role membránových transportérů v chemorezistenci karcinomu
pankreatu při terapii gemcitabinem. Klin Onkol 2010; 23(5): 306–310.
24. Drayton RM, Catto JW.
Molecular mechanisms of cisplatin resistance in bladder cancer. Expert Rev
Anticancer Ther 2012 Feb; 12(2): 271–281.